Novel diagnostic biomarkers in colorectal cancer
AL Zygulska, P Pierzchalski - International journal of molecular sciences, 2022 - mdpi.com
Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of
cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease …
cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease …
Wnt/β-catenin signaling in colorectal cancer: Is therapeutic targeting even possible?
C Disoma, Y Zhou, S Li, J Peng, Z Xia - Biochimie, 2022 - Elsevier
The Wnt/β-catenin signaling pathway has been implicated as the central mechanism that
drives colorectal carcinogenesis. Its activation is historically due to mutation on APC …
drives colorectal carcinogenesis. Its activation is historically due to mutation on APC …
[HTML][HTML] Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Cancer cells can leverage several cell-intrinsic and-extrinsic mechanisms to escape
immune system recognition. The inherent complexity of the tumor microenvironment, with its …
immune system recognition. The inherent complexity of the tumor microenvironment, with its …
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice
J Badia-Ramentol, F Gimeno-Valiente… - Cancer Treatment …, 2023 - Elsevier
Adjuvant chemotherapy following surgical intervention remains the primary treatment option
for patients with localized colorectal cancer (CRC). However, a significant proportion of …
for patients with localized colorectal cancer (CRC). However, a significant proportion of …
Patient derived organoids confirm that PI3K/AKT signalling is an escape pathway for radioresistance and a target for therapy in rectal cancer
K Wanigasooriya, JD Barros-Silva, L Tee… - Frontiers in …, 2022 - frontiersin.org
Objectives Partial or total resistance to preoperative chemoradiotherapy occurs in more than
half of locally advanced rectal cancer patients. Several novel or repurposed drugs have …
half of locally advanced rectal cancer patients. Several novel or repurposed drugs have …
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
E Osterlund, A Ristimäki, S Kytölä, T Kuopio… - Frontiers in …, 2022 - frontiersin.org
Background KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC),
are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a …
are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a …
Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal …
Abstract Background Tumour-infiltrating CD3, CD8 lymphocytes and CD68 macrophages
are associated with favourable prognosis in localised colorectal cancer, but the effect in …
are associated with favourable prognosis in localised colorectal cancer, but the effect in …
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
P Ziranu, A Pretta, M Pozzari, A Maccioni, M Badiali… - Scientific Reports, 2023 - nature.com
Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC)
with mismatch-repair deficiency or high microsatellite instability (dMMR-MSI-H) …
with mismatch-repair deficiency or high microsatellite instability (dMMR-MSI-H) …
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer
V Derangère, J Lecuelle, C Lepage, OAB Salem… - European Journal of …, 2022 - Elsevier
Aim Stratification of colon cancer (CC) of patients with stage II and III for risk of relapse is still
needed especially to drive adjuvant therapy administration. Our study evaluates the …
needed especially to drive adjuvant therapy administration. Our study evaluates the …
CDX2 as a predictive biomarker involved in immunotherapy response suppresses metastasis through EMT in colorectal cancer
Y Wang, Y Kou, R Zhu, B Han, C Li, H Wang… - Disease …, 2022 - Wiley Online Library
Background. Studies have confirmed that Caudal Type Homeobox 2 (CDX2) plays a tumor
suppressor role in colorectal cancer (CRC) and as a prognostic and predictive marker for …
suppressor role in colorectal cancer (CRC) and as a prognostic and predictive marker for …